TY - JOUR
T1 - Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-A systematic review and network meta-Analysis
AU - Navarese, Eliano P.
AU - Gurbel, Paul A.
AU - Andreotti, Felicita
AU - Koøodziejczak, Michalina Marta
AU - Palmer, Suetonia C.
AU - Dias, Sofia
AU - Buffon, Antonino
AU - Kubica, Jacek
AU - Kowalewski, Mariusz
AU - Jadczyk, Tomasz
AU - Laskiewicz, Michaø
AU - Jȩdrzejek, Marek
AU - Brockmeyer, Maximillian
AU - Airoldi, Flavio
AU - Ruospo, Marinella
AU - Servi, Stefano De
AU - Wojakowski, Wojciech
AU - O'Connor, Christopher
AU - Strippoli, Giovanni F.M.
N1 - Funding Information:
Prof. Navarese reports activities as speaker for Sanofi-Regeneron, outside the submitted work. Prof. Gurbel reports serving as a consultant and/or receiving honoraria from Daiichi Sankyo, Lilly, Bayer, AstraZeneca, Merck, Boehringer, Janssen, and CSL Behring; receiving grants from the National Institutes of Health, Daiichi Sankyo/Lilly, CSL, AstraZeneca, Harvard Clinical Research Institute, Bayer, Haemonetics, Duke Clinical Research Institute, Sinnowa, Coramed, and Accumetrics, outside the submitted work. Prof. Andreotti reports receiving honoraria for activities as speaker, consultant or monitor for Amgen, Bayer, Boehringer Ingelheim, BMS-Pfizer, Daiichi Sankyo and Eli Lilly, outside the submitted work. Dr. Palmer reports grants from Amgen Dompe, outside the submitted work. Prof Kubica reports a consulting fee from AstraZeneca. Prof O’ Connor reports salary support through a NHLBI research grant, funding from Actelion Pharmaceuticals Ltd, Amgen Inc., Biscardia LLC, Faculty Connection, GE Healthcare, Ikaria, Novella Clinical Inc., Pfizer Inc., Pozen, and Roche Diagnostics; serving as a consultant for Novartis, Heartware, ResMed, Johnson & Johnson, Gilead, Critical Diagnostics, BG Medicine, Otsuka, Astellas, Cytokinetics, and Capricor, stock options in Neurotronik/Interventional Autonomics Corporation, outside the submitted work. Prof O’ Connor serves as a Journal editor for American College of Cardiology. GFMS is scientific consultant for Diaverum Sweden, outside the present work. Remaining authors have no conflicts to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials, as detailed online in our guide for authors.
Publisher Copyright:
© 2017 Navarese et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2017/2
Y1 - 2017/2
N2 - Background Interventional diagnostic and therapeutic procedures requiring intravascular iodinated contrast steadily increase patient exposure to the risks of contrast-induced acute kidney injury (CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hospitalization. The aim of this study was to investigate the efficacy of pharmacological and non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular invasive procedures with iodinated contrast. Methods and findings MEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and presentations from major cardiovascular and nephrology meetings were searched, up to 22 April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI (alone or in combination) when added to saline versus each other, saline, placebo, or no treatment in patients undergoing cardiovascular invasive procedures with administration of iodinated contrast. Two reviewers independently extracted trial-level data including number of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were pooled using network meta-Analysis. Treatment estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible. Saline plus N-Acetylcysteine (OR 0.72, 95%CrI 0.57±0.88), ascorbic acid (0.59, 0.34±0.95), sodium bicarbonate plus N-Acetylcysteine (0.59, 0.36±0.89), probucol (0.42, 0.15±0.91), methylxanthines (0.39, 0.20±0.66), statin (0.36, 0.21±0.59), device-guided matched hydration (0.35, 0.12±0.79), prostaglandins (0.26, 0.08±0.62) and trimetazidine (0.26, 0.09±0.59) were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01± 0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01±0.59) were associated with lower mortality compared to saline. Conclusions Currently recommended treatment with saline as the only measure to prevent CIAKI during cardiovascular procedures may not represent the optimal strategy. Vasodilators, when added to saline, may significantly reduce the odds of CIAKI following cardiovascular procedures.
AB - Background Interventional diagnostic and therapeutic procedures requiring intravascular iodinated contrast steadily increase patient exposure to the risks of contrast-induced acute kidney injury (CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hospitalization. The aim of this study was to investigate the efficacy of pharmacological and non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular invasive procedures with iodinated contrast. Methods and findings MEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and presentations from major cardiovascular and nephrology meetings were searched, up to 22 April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI (alone or in combination) when added to saline versus each other, saline, placebo, or no treatment in patients undergoing cardiovascular invasive procedures with administration of iodinated contrast. Two reviewers independently extracted trial-level data including number of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were pooled using network meta-Analysis. Treatment estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible. Saline plus N-Acetylcysteine (OR 0.72, 95%CrI 0.57±0.88), ascorbic acid (0.59, 0.34±0.95), sodium bicarbonate plus N-Acetylcysteine (0.59, 0.36±0.89), probucol (0.42, 0.15±0.91), methylxanthines (0.39, 0.20±0.66), statin (0.36, 0.21±0.59), device-guided matched hydration (0.35, 0.12±0.79), prostaglandins (0.26, 0.08±0.62) and trimetazidine (0.26, 0.09±0.59) were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01± 0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01±0.59) were associated with lower mortality compared to saline. Conclusions Currently recommended treatment with saline as the only measure to prevent CIAKI during cardiovascular procedures may not represent the optimal strategy. Vasodilators, when added to saline, may significantly reduce the odds of CIAKI following cardiovascular procedures.
UR - http://www.scopus.com/inward/record.url?scp=85011321148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011321148&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0168726
DO - 10.1371/journal.pone.0168726
M3 - Article
C2 - 28151965
AN - SCOPUS:85011321148
SN - 1932-6203
VL - 12
JO - PloS one
JF - PloS one
IS - 2
M1 - e0168726
ER -